{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:18:32Z","timestamp":1762917512361},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jocn.2013.10.041","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T00:45:27Z","timestamp":1398732327000},"page":"1094-1101","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson\u2019s disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Chang-Qing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang-Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Guang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2013.10.041_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","article-title":"Description of Parkinson\u2019s disease as a clinical syndrome","volume":"991","author":"Fahn","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2013.10.041_b0010","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(05)70801-1","article-title":"Parkinson\u2019s disease in China: prevalence in Beijing, Xian, and Shanghai","volume":"365","author":"Zhang","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2013.10.041_b0015","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00702-003-0059-x","article-title":"Dopamine receptor agonists in the therapy of Parkinson\u2019s disease","volume":"111","author":"Foley","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jocn.2013.10.041_b0020","first-page":"701","article-title":"Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson\u2019s disease","volume":"57","author":"Radad","year":"2005","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jocn.2013.10.041_b0025","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1474-4422(07)70218-1","article-title":"Fibrotic heart\u2013valve reactions to dopamine\u2013agonist treatment in Parkinson\u2019s disease","volume":"6","author":"Antonini","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2013.10.041_b0030","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/mds.23470","article-title":"The risk of valvular regurgitation in patients with Parkinson\u2019s disease treated with dopamine receptor agonists","volume":"26","author":"Rasmussen","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2013.10.041_b0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3949\/ccjm.78gr.11005","article-title":"Updates in the medical management of Parkinson disease","volume":"79","author":"Fernandez","year":"2012","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jocn.2013.10.041_b0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/WCO.0b013e3283542fc2","article-title":"Therapies in Parkinson\u2019s disease","volume":"25","author":"Jankovic","year":"2012","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.jocn.2013.10.041_b0045","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.1007\/s00415-011-6024-y","article-title":"Continuous dopaminergic stimulation and novel formulations of dopamine agonists","volume":"258","author":"Stocchi","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2013.10.041_b0050","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.clinthera.2009.10.018","article-title":"Pharmacokinetics of a once\u2013daily extended\u2013release formulation of pramipexole in healthy male volunteers: three studies","volume":"31","author":"Jenner","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.jocn.2013.10.041_b0055","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.clinthera.2012.02.008","article-title":"Steady\u2013state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open\u2013label, randomized, phase I multiple dose studies","volume":"34","author":"Elshoff","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.jocn.2013.10.041_b0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/WNF.0b013e318176c505","article-title":"Pharmacokinetic and pharmacodynamic comparison of ropinirole 24\u2013hour prolonged release and ropinirole immediate release in patients with Parkinson\u2019s disease","volume":"32","author":"Tompson","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jocn.2013.10.041_b0065","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/mds.20602","article-title":"Suboptimal medication adherence in Parkinson\u2019s disease","volume":"20","author":"Grosset","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2013.10.041_b0070","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/mds.22112","article-title":"Adherence to antiparkinson medication in a multicenter European study","volume":"24","author":"Grosset","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2013.10.041_b0075","first-page":"S66","article-title":"SP511 investigators. Rotigotine transdermal delivery system (TDS) (SPM962) \u2013 A multi\u2013center, double\u2013blind, randomized, placebo\u2013controlled trial to assess the safety and efficacy of rotigotine TDS in patients with advances Parkinson\u2019s disease","volume":"7","author":"Quinn","year":"2001","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jocn.2013.10.041_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jocn.2013.10.041_b0085","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.60.12.1721","article-title":"A controlled trial of rotigotine monotherapy in early Parkinson\u2019s disease","volume":"60","author":"The Parkinson Study Group","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2013.10.041_b0090","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/archneur.64.5.676","article-title":"Transdermal rotigotine: double\u2013blind, placebo\u2013controlled trial in Parkinson disease","volume":"64","author":"Jankovic","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2013.10.041_b0095","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.21741","article-title":"Rotigotine transdermal patch in early Parkinson\u2019s disease: a randomized, double\u2013blind, controlled study versus placebo and ropinirole","volume":"22","author":"Giladi","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2013.10.041_b0100","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1212\/WNL.0b013e31822affb0","article-title":"Extended\u2013release pramipexole in early Parkinson disease: a 33\u2013week randomized controlled trial","volume":"77","author":"Poewe","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2013.10.041_b0105","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","article-title":"Advanced Parkinson disease treated with rotigotine transdermal system PREFER study","volume":"68","author":"LeWitt","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2013.10.041_b0110","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","article-title":"Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double\u2013blind, double\u2013dummy, randomised controlled trial","volume":"6","author":"Poewe","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2013.10.041_b0115","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","article-title":"Ropinirole 24\u2013hour prolonged release randomized, controlled study in advanced Parkinson disease","volume":"68","author":"Pahwa","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2013.10.041_b0120","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1212\/WNL.0b013e31822affdb","article-title":"Extended\u2013release pramipexole in advanced Parkinson disease: a randomized controlled trial","volume":"77","author":"Schapira","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2013.10.041_b0125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","article-title":"Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double\u2013blind, randomized, placebo\u2013controlled study (RECOVER)","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2013.10.041_b0130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.parkreldis.2008.07.004","article-title":"Dopamine agonists in the treatment of early Parkinson\u2019s disease: a meta\u2013analysis","volume":"15","author":"Baker","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jocn.2013.10.041_b0135","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1742-1241.2009.02027.x","article-title":"Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson\u2019s disease: a meta analysis","volume":"63","author":"Talati","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jocn.2013.10.041_b0140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/mds.23517","article-title":"Meta\u2013analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson\u2019s disease","volume":"26","author":"Stowe","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2013.10.041_b0145","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/mds.23638","article-title":"Parkinson study group. determination of minimal clinically important change in early and advanced Parkinson\u2019s disease","volume":"26","author":"Hauser","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2013.10.041_b0150","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.parkreldis.2008.12.007","article-title":"Pharmacologic treatment of advanced Parkinson\u2019s disease: a meta\u2013analysis of COMT inhibitors and MAO\u2013B inhibitors","volume":"15","author":"Talati","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jocn.2013.10.041_b0155","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/11319860-000000000-00000","article-title":"Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson\u2019s disease: meta\u2013analysis of randomized controlled trials","volume":"33","author":"Kulisevsky","year":"2010","journal-title":"Drug Saf"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586814000605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586814000605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T11:21:18Z","timestamp":1538652078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586814000605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0967586814000605"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2013.10.041","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2013.10.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}